share_log

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5:募资说明书
美股SEC公告 ·  05/15 12:44

Moomoo AI 已提取核心信息

Allarity Therapeutics Inc. has announced an amendment to its Sales Agreement with Ascendiant Capital Markets, LLC, increasing the total amount of common stock it may offer and sell to $24,000,000. This update, detailed in Supplement No. 10 to the Prospectus Supplement dated March 19, 2024, follows the company's public float exceeding $75.0 million on May 2, 2024, which lifted the previous sales limitation under General Instruction I.B.6 of Form S-3. As of May 14, 2024, Allarity Therapeutics has already sold 17,959,714 shares for gross proceeds of $21,995,067. The new prospectus supplement, dated May 15, 2024, allows for the sale of additional common stock up to the new limit, inclusive of the gross proceeds already obtained through the Sales Agreement.
Allarity Therapeutics Inc. has announced an amendment to its Sales Agreement with Ascendiant Capital Markets, LLC, increasing the total amount of common stock it may offer and sell to $24,000,000. This update, detailed in Supplement No. 10 to the Prospectus Supplement dated March 19, 2024, follows the company's public float exceeding $75.0 million on May 2, 2024, which lifted the previous sales limitation under General Instruction I.B.6 of Form S-3. As of May 14, 2024, Allarity Therapeutics has already sold 17,959,714 shares for gross proceeds of $21,995,067. The new prospectus supplement, dated May 15, 2024, allows for the sale of additional common stock up to the new limit, inclusive of the gross proceeds already obtained through the Sales Agreement.
Allarity Therapeutics Inc.宣布修订其与Ascendiant Capital Markets, LLC的销售协议,将其可能发行和出售的普通股总额增加到2400万美元。本次更新详见2024年3月19日招股说明书补充文件第10号补编,此前该公司于2024年5月2日公开上市量超过7,500万美元,这取消了先前根据S-3表格I.B.6号一般指令规定的销售限制。截至2024年5月14日,Allarity Therapeutics已经出售了17,959,714股股票,总收益为21,995,067美元。2024年5月15日的新招股说明书补充文件允许在新的限额内出售额外的普通股,包括通过销售协议获得的总收益。
Allarity Therapeutics Inc.宣布修订其与Ascendiant Capital Markets, LLC的销售协议,将其可能发行和出售的普通股总额增加到2400万美元。本次更新详见2024年3月19日招股说明书补充文件第10号补编,此前该公司于2024年5月2日公开上市量超过7,500万美元,这取消了先前根据S-3表格I.B.6号一般指令规定的销售限制。截至2024年5月14日,Allarity Therapeutics已经出售了17,959,714股股票,总收益为21,995,067美元。2024年5月15日的新招股说明书补充文件允许在新的限额内出售额外的普通股,包括通过销售协议获得的总收益。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息